Resource Summary Report

Generated by PRECISE-TBI on Aug 10, 2026

Anti-Pan Keratin (AE1/AE3/PCK26) Primary Antibody

RRID:AB_2941938
Type: Antibody

Proper Citation

Roche Cat# 760-2595, RRID:AB_2941938

Antibody Information

URL: http://antibodyregistry.org/AB_2941938

Proper Citation: Roche Cat# 760-2595, RRID:AB_2941938

Target Antigen: Keratin

Host Organism: mouse

Clonality: cocktail

Antibody Name: Anti-Pan Keratin (AE1/AE3/PCK26) Primary Antibody

Description: This cocktail targets Keratin

Target Organism: human

Clone ID: AE1/AE3/PCK26

Antibody ID: AB_2941938

Vendor: Roche

Catalog Number: 760-2595

Alternative Catalog Numbers: 760-2135

Record Creation Time: 20250819T204644+0000

Record Last Update: 20250819T204726+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Pan Keratin (AE1/AE3/PCK26) Primary Antibody.

No alerts have been found for Anti-Pan Keratin (AE1/AE3/PCK26) Primary Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at PRECISE-TBI .

Lee LH, et al. (2025) Defining Non-small Cell Lung Cancer Tumor Microenvironment Changes at Primary and Acquired Immune Checkpoint Inhibitor Resistance Using Clinical and Real-World Data. Cancer research communications, 5(6), 1049.

Solomon BJ, et al. (2025) The Impact of the Tumor Microenvironment on the Effect of IL-1?? Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials. Cancer research communications, 5(4), 632.

Blackman A, et al. (2024) MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model. Cancer research communications, 4(9), 2525.

Kuzmin E, et al. (2024) Evolution of chromosome-arm aberrations in breast cancer through genetic network rewiring. Cell reports, 43(4), 113988.

Taifour T, et al. (2023) The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer. Immunity, 56(12), 2755.